Author
Unnikrishnan is currently Senior Associate Editor with BW Businessworld at its Mumbai Bureau. During his two decades long journalistic career, he has received several media awards and recognitions. His articles on healthcare, life sciences and intellectual property rights (IPR) have been republished by several international blogs and journals.
Sanofi India's board has recommended to elect Aditya Narayan as the new chairman of the board after Mallya conveyed his decision not to seek re-election
Read More
Biocon is currently one of the large insulins producers in Asia and it has a range of products including rh-Insulin (Insugen) and Insulin Glargine (Basalog) in India and several emerging markets.
Read More
The US Food and Drug Administration has warned Indian generic drugmaker Emcure Pharmaceuticals, saying it repeatedly fudged test records at its plant at Pune
Read More
Sun Pharma, promoted and led by the astute billionaire, Dilip Shanghvi, has always followed an inorganic growth strategy both in India and abroad.
Read More
With a four-year average of 11.9 per cent CAGR in sales and 34.7 per cent growth in net profits during 2011-2015, BPCL was the third fastest growing company in India in BW Businessworld’s 2016 list of super heavyweights.
Read More
Despite currency headwinds and a challenging industry landscape, the company scored an average growth of 26.1 per cent in sales and 27.6 per cent in net profit over the last 4 years
Read More
The financial pressure that haunts the liquor baron in India of late may force him to dilute a part of his most valued stake in United Breweries as well
Read More
The negative perception about Vijay Mallya as a financial offender following the wilful defaulter tag and the demand for his arrest by the lenders should be a matter of concern for Sanofi India and Bayer Cropsciences
Read More
Adar Poonawalla is moving away from fast cars and flamboyance, and into new areas like hospitality and real estate
Read More
India, with the world’s second largest diabetic population, was one of Lilly’s first few targeted markets for this biological drug soon after its launch in the US
Read More
